Shots: The approval is based on P-II ZUMA-2 study assessing Tecartus in 74 patients with r/r MCL prior treated with anthracycline/ bendamustine-containing CT, an anti-CD20 Ab therapy and a BTK inhibitor (ibrutinib or acalabrutinib) The study demonstrated an OR rate (93 %) with CR (67%), as assessed by an Independent RRC following a single infusion. […]Read More
